

Bromley Clinical Commissioning Clinical Executive Group Date: 30 July 2015

ENCLOSURE 10

Title: Phlebotomy Review PID

DIRECTOR RESPONSIBLE: Mark Needham (Director of Commissioning)

CLINICAL LEAD: Dr Jon Doyle

AUTHOR: Alexandra Bigg (Coordination and Delivery Manager)

SUMMARY:

The project mandate was approved on 30 April 2015 to undertake this review. It is anticipated that the review will completed in 3-4 months from the first meeting of the Steering Group. At the end of the review recommendations will be made to the Clinical Executive Group, which may lead to a business case for service change.

Our vision is to commission **swift**, **equitable** and **local** access to a phlebotomy service offering both booked and walk-in appointments. This will also help GPs to make a **timely diagnosis** of a patient's condition.

The aims of the review are:

- 1) To gain a full understanding of current phlebotomy provision (where phlebotomy is offered and when, and what the balance of activity is between hospital, community and GP services) and the extent to which it is meeting the needs of service users.
- 2) To observe examples of best practice in other boroughs to help inform the options appraisal.
- 3) To make recommendations for the future of phlebotomy provision.

Key milestones:

August 15 - Draft engagement plan and baseline report on current provision complete

September 15 – First Steering Group

October 15 – Report on other local models of delivery complete

November 15 – Engagement report complete

January 16 (latest) – Options appraisal and recommendations to CEG

KEY ISSUES:

History: The revised 2011 LES for phlebotomy has doubled the phlebotomy activity in GP practices. However, there are still issues with inequity of provision and long waiting times in walk-in clinics. In light of previous work, it is important that:

Clinical Chair: Dr Andrew Parson 1 Chief Officer: Dr Angela Bhan

Clinical Commissioning Group

a) any future changes to phlebotomy provision must be agreed as a result of comprehensive patient and service provider engagement to ensure that they can be implemented successfullyb) any future changes consider current and predicted activity levels carefully so that the phlebotomy service will meet the aims of swift, equitable and local access.

Governance: The review is likely to garner high levels of public and patient interest. The review and the recommendations that follow must therefore be credible. It was agreed by the CEG on 25/6/15 that the CCG would chair the review. A Steering Group will be established and chaired by Dr Jon Doyle (Clinical Lead) and will include a representative from key stakeholders: KCH, BHC, LMC, HWB councillor, Healthwatch and patient representation. The Steering Group will provide an overall steer for the review, analyse the current provision and the outcomes of the engagement, and put together the options appraisal and recommendations paper for CEG.

Engagement: Healthwatch will support the CCG with patient engagement, especially with reaching seldom heard groups. The scope of the review will be presented carefully in order to manage patient expectations. Feedback will be sought from GP practices as requestors of blood tests. Estimated cost £6k.

COMMITTEE INVOLVEMENT:

Planned Care Working Group (review of draft PID)

PUBLIC AND USER INVOLVEMENT:

None as yet

IMPACT ASSESSMENT:

The review itself will have no impact on health inequalities. The vision for phlebotomy is to increase equity in access to services, particularly for vulnerable or frail patients. However, we have considered how we will ensure that the review itself meets the equality impact assessment criteria.

RECOMMENDATIONS:

The Committee is asked to:

1. Approve the PID

ACRONYMS

DIRECTORS CONTACT:

Name: Mark Needham
E-Mail: m.needham@nhs.net
Telephone: 01689 866 167

AUTHOR CONTACT:

Name: Alexandra Bigg

E-Mail: <u>alexandra.bigg1@nhs.net</u> Telephone: 01869 866 555

Project Lead D	Date	Clinical Lead
Alexandra Bigg 23	23/07/2015	Dr Jon Doyle

Project Information

Project Description

This review of the phlebotomy service is focused on **patient access** to having a blood sample taken when requested by a GP. The testing of the sample and returning the results to the referrer has already been reviewed and is in undergoing service improvement as part of the Direct Access Diagnostics initiative led by Richard Dolby.

The project mandate was approved on 30 April 2015 to undertake this review. It is anticipated that the review will completed in 3-4 months from the first meeting of the Steering Group. At the end of the review recommendations will be made to the Clinical Executive Group, which may lead to a business case for service change.

Governance: The review is likely to garner high levels of public and patient interest. Almost all people require a blood test on at least one occasion and expectations will need to be managed carefully given historical issues with the service. The review and the recommendations that follow must therefore be credible. It was agreed by the CEG on 25/6/15 that the CCG would chair the review. A Steering Group will be established and chaired by Dr Jon Doyle (Clinical Lead) and will include a representative from key stakeholders: KCH, BHC, LMC, HWB councillor, Healthwatch and patient representation. The Steering Group will provide an overall steer for the review, analyse the current provision and the outcomes of the engagement, and put together the options appraisal and recommendations paper for CEG.

Draft engagement plan:

- It is anticipated that the engagement work will take 2-3 months to complete, including write-up. The engagement plan will be agreed by the Steering Group.
- Patients (and wider public): Distribution of a standard survey asking for feedback on the experience of accessing the phlebotomy service via CCG and partner websites and having hard copies at practices and phlebotomy clinics (support from Healthwatch); an event for the PAG and key voluntary sector organisations; events to reach seldom heard groups (support from Healthwatch).
- GP practices (as requestors of blood tests): Raise awareness of the review through the GP bulletin and cluster meetings; distribution of a standard survey asking for feedback on what works well with current provision and how it could be improved; attendance at HCA and PN forums to gather feedback; possible focus group of GPs to gather feedback

Project Aims

Our vision is to commission **swift, equitable** and **local** access to a phlebotomy service offering both booked and walk-in appointments. This will also help GPs to make a **timely diagnosis** of a patient's condition.

The aims of the review are:

- 1) To gain a full understanding of current phlebotomy provision (where phlebotomy is offered and when, and what the balance of activity is between hospital, community and GP services) and the extent to which it is meeting the needs of service users.
- 2) To observe examples of best practice in other boroughs to help inform the options appraisal.
- 3) To make recommendations for the future of phlebotomy provision.

Rationale

Work to improve access to phlebotomy services has been ongoing since 2010:

- In March 2011 a business case was approved to revise the LES for phlebotomy in order to increase local access and bookable appointments. This resulted in an increase in the number of practices offering phlebotomy (from 10 to 22) and phlebotomy activity in practices has more than doubled since 2010.
- However, the review of local enhanced services conducted in 2013-14 found that access and waiting times for phlebotomy were still a problem. It found that access is **not equitable**, with limited local provision offered to patients living near Bromley Town Centre, Penge and Petts Wood. Waiting times at walk-in clinics were still long, with patients sometimes having to **wait over 90 minutes** to have their blood taken. Clinical Exec approved an **improvement plan to address the challenges at KCH in** September 2014, but the implementation of this has held up due to the nature of the pathology block contract and moves to transfer the pathology service to Viapath.
- In March 2015 the Governing Body noted that although phlebotomy services have improved considerably, there are still concerns over the current provision and that an **engagement plan should be developed alongside Healthwatch** to seek feedback from patients. Following this, recommendations would be made for changes.

Existing GP contracts for this enhanced service have been re-issued under an NHS standard contract from 1 April 2015 until March 2018 with a 6 month notice period for termination. To date, 25 practices have signed up to the enhanced service for 2015-18.

In light of previous work, it is important that:

- a) Any future changes to phlebotomy provision must be agreed as a result of comprehensive patient and service provider engagement to ensure that they can be implemented successfully.
- b) Any future changes consider current and predicted activity levels carefully so that the phlebotomy service will meet the aims of a swift, equitable and local access.

A diagnostic review is therefore proposed that engages both patients and service providers so that is seen as credible by all stakeholders.

2. PID 1

Key Area of Focus	Stakehold	ler engagen	nent with (a)	service use	ers - natient	s and GPs	as referre	rs and (b) pro	viders - GPs	Bromle	v Healthca	are and
Ney Alea of Focus	KCH.	er engagen	ient with (a)	Service use	ors - patient	3 and Or 3	as referre	is and (b) pro	videis - Oi s	s, Dioinie	y i lealtile	ile alla
	Options a	ppraisal and	d recommend	dations.								
	Pro	ject Scope	- IN					Projec	t Scope - O	UT		
GP registered patier	nts (adults a	nd children)	in Bromley f	or whom a	blood test	Patients		a blood test h				ealthca
h	as been requ	uested by th	eir GP pract	ice			C	ontext (e.g. o	utpatient ap	pointmen	t)	
Project Objective												
Statements of Speci	fic, Measur	eable, Achi	evable, Rel	evant, Tim	ely outcon	nes						
					nostic repo							
		Write up	an options a	ppraisal an	d recomme	ndations to	go Clinic	al Executive (Group			
	- /			and a state								
Expected Benefit	s (or an ar	nenaea s	ervice foli	owing the	e review)							
	he benefit?				easure/KPI			e of Benefit		Who k	enefits?	
mproved access acre	oss the boro	ugh and	Provision is				Quality		Patients			
cross age range			travel more						Practices	Practices		
			taken at a b timeframe.	оокеа арро	ointment wit	inin Y						
Shorter waiting times	at walk-in cl	inics	Local performance indicator in service			Quality		Patients				
onortor watting times	at Wallt III of		specification - X minutes maximum waiting			Quanty		Practices	3			
			time									
Shorter waiting times	to get a boo	ked	Local performance indicator in service			Quality		Patients				
ppointment			specification - X days maximum waiting time				Practices	;				
Key Milestones (s	tages of t	he projec	t plan)									
tart Date	30/04/2015	5										
Decide			Des	ign			Devel	op (**TBC**)		Deliver	(**TBC**))
		Baseline		Other								
Gate 2	Draft	report on	First	models of		Options				1		
(PID	engagem	current	Steering	delivery	Engagem	appraisal				ĺ		
approval	ent plan	provision	Group	report	ent report	at CEG 07/01/16				<u> </u>		
arget			17/9/15 (at			(at						
ompletion ate 30/07/15	31/08/15	31/08/15		31/10/15	30/11/15							
Project Resource	Requiren	nents										
roiect Team:			Role:						commitme			
	Project Manager				2-3 days per week							
Alexandra Bigg										K		
Alexandra Bigg Janet Edmonds Jon Doyle			Head of Clir Clinical Lea	nical Progra	ammes - pla	nned care	oversight	1 hou	ays per week ur per week ur per week	·K		

Date 30/07/15 31	/08/15 31/08/15	latest) 31/10	/15 30/11/15 latest)				
Project Resource Requirements							
Project Team:		Role:			Time c	ommitment:	
Alexandra Bigg		Project Manager			2-3 day	/s per week	
Janet Edmonds		Head of Clinical Pr	ogrammes - planned care	oversight	1 hour	per week	
Jon Doyle		Clinical Lead			1 hour	per week	
Sam Burrows		Information Analys			1 hour	per week	
Liz Munro		Communications a	nd Engagement		2-3 hou	ırs per week	
TBC		Project Support Of	icer		1 day p	er week	
TBC		Finance			Not rec	uired as yet	
Additional Resource Requirements:							
None as vet							

2. PID

Quality Implica	Quality Implications (of an amended service following the review)							
Area of Quality	Quality Domain	Description of Quality impact	Positive, Negative, Not	Conseq uence	Likely- hood	Score		
	Preventing people from dying prematurely	n/a	No impact			0		
Clinical Effectiveness		Improved access to phlebotomy services - closer to home and shorter waits so blood test results can be received and analysed more quickly to inform ongoing treatment.	Positive			0		
	3. Helping people to recover from episodes of ill health	Improved access to phlebotomy services - closer to home and shorter waits so blood test results can be received and analysed more quickly to inform ongoing treatment.	Positive			0		
Patient Experience	4. Ensuring that people have a positive experience of care	Improved access to phlebotomy services - closer to home and shorter waits so that patients are not unnecessarily inconvenienced.	Positive			0		
Patient Safety	5. Treating and caring for people in a safe environment and protecting them from avoidable harm	The project is focused on access, not safety. Any changes to phlebotomy service provision that come out of the review would be subject to existing service specification quality and safety requirements.	No impact			0		
Workforce		Possible change in distribution/location of staff offering the phlebotomy service - mainly HCAs. E.g. if an increased number of GPs offer phlebotomy and therefore fewer walk-in appts are required. Need to bear in mind the KCH block contract for pathology services and the staff employed through the outpatients budget.	Not yet known			0		
Equality		Increase equity in terms of access to services, particularly for vulnerable or frail patients.	Positive			0		

ESTIMATED ANNUALI	ESTIMATED ANNUALISED IMPACT ON TARGET / BUDGET FOR THIS ACTIVITY											
(all categories of benefit	(all categories of benefit and cost to be included, and net benefit calculated for financial projects)											
Gross BENE	EFIT / Targe	t Units (e.g	clients/con	sultations)		INVESTI	VIENT / D	EVELOP	MENT CO	ST (£000s)		
Benefit Description and Units	No. of Units / Activity	Cost / Tariff (£000)	Full Year Benefit	Full/ Part Year 2015/16	Full Year 2015/16	Category	No. of Units / Activity	Rate (£000 / Unit)		Full/ Part Year 13/14		Full Year 15/16
Not yet known						Engagement	n/a	n/a	6.0			
						NB. £4k of engagement						
						costs will be covered by						
						the Comms and						
						Engagement money						
						already set aside for						
						Healthwatch work						
Gross BENEFIT Totals	s:		0.0	0.0	0.0	Investment / Development	Costs 1	otals:	6.0	0.0	0.0	0.0

Activity Target Units						
Activity Description	HRG / ICD10 or other measurable unit of activity	Full/ Part Year 15/16	Full Year 15/16			
Not yet known						
Activity Impact Totals:						

NET BENEFIT (£000s)					
	Full/Part Year 2015/16	Year	Full Year 2016/17		
Gross Benefits	0.0	0.0			
Costs	6.0	0.0			
Net Benefits	-6.0	0.0			

Risk and Issues Log	
	Confirmed
Stakeholder Plan	
	In draft - to be confirmed at Steering Group

Gate 2 Title	Sign-off / Recommendation / Decision	Name	Date
Project Lead		Alexandra Bigg	
Clinical Lead		Jon Doyle	
Finance Lead			
Performance Manager			
Quality Director			
Programme Board			
Clinical Executive Group			

2. PID

INITIAL SCREENING FOR EQUALITY IMPACT ASSESSMENT

At this stage, the following questions need to be considered:

Name	Name of Policy / Strategy / Service redesign etc.					
1	What is the name of the policy, strategy or project?					
	Phlebotomy review					
2	Briefly describe the aim of the policy, strategy or project. What needs or designed to meet?	duty is i	t			
	 To gain a full understanding of current phlebotomy provision (where phlebotomy is offered and when, and what the balance of activity is between hospital, community and GP services) and the extent to which it is meeting the needs of service users. To observe examples of best practice in other boroughs to help inform the options appraisal. To make recommendations for the future of phlebotomy provision. 					
3	Is there any evidence or reason to believe that the policy, strategy or project could have an adverse or negative impact on any group/s?	Yes	No			
4	Is there any evidence or other reason to believe that different groups have different needs and experiences that this policy is likely to assist i.e. there might be a <i>relative</i> adverse effect on other groups?	Yes	<u>No</u>			
	We recognise that frail and vulnerable people, workers, children and those with LTCs have different needs, and therefore the engagement plan looks to gather the views of as many different groups as possible in order to ensure that no group is adversely affected.					
5	Has prior consultation taken place with organisations or groups which has indicated a pre-existing problem which this policy, strategy, service redesign or project is likely to address?	Yes	<u>No</u>			
	There was some consultation in the lead up to the revised 2011 LES, but this did not reveal a problem with a particular group. The proposed engagement plan will be a much more comprehensive engagement piece.					

Signed by the manager undertaking the assessment:	Alexandra Bigg
Date Completed:	24/7/15
Job Title:	Coordination and Delivery Manager

On Completion of Stage 1 – A full impact assessment (Appendix 2) will normally be required if you have answered YES to one or more of questions 3, 4 and 5 above